Skip to main content
. 2022 Feb 2;2(2):e0000156. doi: 10.1371/journal.pgph.0000156

Table 2. Crude and adjusted hazard ratios for factors associated with retention in the Cervical Cancer Screening Cascade.

Univariable analyses Multivariable analysis
n = 1251 n = 1251
HR 95% CI P value HR 95% CI P value
Age, years
 18–25 2.02 1.61–2.54 1.40 1.07–1.82
 25–44 1 - <0.001 1 - 0.025
 >45 2.19 1.71–2.80 1.50 1.12–2.03
Relationship
 Single 0.78 0.67–0.90 0.83 0.71–0.98
 Relationship 1 - 0.002 1 - 0.076
 Separated 0.98 0.85–1.14 0.92 0.78–1.08
Employment
 Unemployed 1 - 1 -
 Employed 0.98 0.86–1.12 <0.001 0.93 0.81–1.06 0.388
 Student 0.45 0.29–0.70 0.81 0.51–1.30
Parity
 0 1 - 1 -
 1 to 3 1.77 1.44–2.19 <0.001 1.46 1.15–1.86 0.008
 >3 1.37 1.08–1.73 1.41 1.07–1.85
HIV RNA viral load at VIA screening, copies/mm 3
 <50 1 - 1 -
 50–1000 1.21 0.99–1.47 <0.001 1.19 0.96–1.47 <0.001
 >1000 1.36 1.19–1.55 1.33 1.16–1.53
Calendar period enrolled
 Early years: 2012–2014 1 - 1 -
 Later years: 2015–2017 1.31 1.16–1.49 <0.001 1.26 1.10–1.43 <0.001
Nadir CD4 cell count, cells/mm3
 <200 1 -
 200–349 1.02 0.86–1.29
 350–500 1.40 1.86–1.26 0.977
 >500 1.02 0.84–1.24
HIV RNA viral load at ART enrollment, copies/mm 3
 <50 1 -
 50–1000 0.79 0.62–1.01 0.150
 >1000 0.96 0.84–1.10

Retention in the Cervical Cancer Screening Cascade is defined as all women living with HIV (WLHIV) achieving rescreening in either arm (screening or preventative treatment) of the Secondary Cervical Cancer Prevention Cascade. HR: hazards ratio; n: number of women; CI: confidence interval; HIV: human immunodeficiency virus; RNA: Ribonucleic acid; VIA: visual inspection with acetic acid; n: number of WLHIV.